During Q2FY23, Supriya Lifescience Ltd (SLL) reported Revenue of INR 1,120 Mn (-25.33% YoY / +10.89% QoQ). Such growth was mainly driven by strong sales from Analgesic/Anestetic segment which contributed 56% to the topline against 36% in same period last year.